Day One Biopharmaceuticals Inc (DAWN) Stock Price, Quote & News

Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 484 0899

Website: dayonebio.com

Address:

1800 Sierra Point Parkway, Suite 200, Brisbane, United States

GriZlyBeAr Jan. 21 at 12:53 AM

$DAWN holy fook

1 · Reply

Buckeye80 Jan. 21 at 12:53 AM

$DAWN bid 13.20

0 · Reply

MeganF0x Jan. 21 at 12:04 AM

} There’s no denying @CoralSharkie owned last year and set the bar on a whole new level 🔥 }If you’re not following yet, take a second to do so. It’s quick, free, and worth it!! Appreciate you love xoxo😘 $MSGY $ACHC $DAWN $BMNZ >>> on watch as well

0 · Reply

Xanderzzzzzzz Jan. 20 at 11:24 PM

$DAWN

0 · Reply

Buckeye80 Jan. 20 at 11:18 PM

$DAWN bid 12.50

0 · Reply

GriZlyBeAr Jan. 20 at 10:11 PM

$DAWN zero sellers, you can sell if you want, looks like there is plenty on the bid

0 · Reply

GriZlyBeAr Jan. 20 at 9:54 PM

$DAWN love that this is under the radar with less than 2000 watchers

2 · Reply

GriZlyBeAr Jan. 20 at 9:44 PM

$DAWN all the shares are locked by insiders and institutions…when do the shorts cover…

0 · Reply

copywrites Jan. 20 at 9:36 PM

$DAWN still running AH

1 · Reply

GriZlyBeAr Jan. 20 at 9:32 PM

$DAWN 👀

0 · Reply

Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 5:00 PM EST - 9 days ago

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Jan 6, 2026, 9:02 AM EST - 14 days ago

Day One Completes Acquisition of Mersana Therapeutics

Dec 18, 2025, 3:46 PM EST - 4 weeks ago

Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish

Dec 16, 2025, 8:30 AM EST - 5 weeks ago

Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 2 months ago

Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 18, 2025, 8:30 AM EST - 2 months ago

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 10:15 AM EST - 2 months ago

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

MRSN

Nov 13, 2025, 6:00 AM EST - 2 months ago

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

Nov 10, 2025, 7:00 AM EST - 2 months ago

Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Nov 4, 2025, 8:36 PM EST - 2 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:00 PM EST - 2 months ago

Day One Reports Third Quarter 2025 Financial Results and Corporate Progress

Oct 21, 2025, 8:30 AM EDT - 3 months ago

Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025

Aug 7, 2025, 10:26 PM EDT - 5 months ago

Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade)

Aug 5, 2025, 9:19 PM EDT - 5 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:00 PM EDT - 6 months ago

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

Jul 22, 2025, 8:30 AM EDT - 6 months ago

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

Jun 10, 2025, 8:30 AM EDT - 8 months ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Jun 4, 2025, 8:59 PM EDT - 8 months ago

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

May 6, 2025, 10:12 PM EDT - 9 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 9 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Apr 22, 2025, 8:30 AM EDT - 9 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Apr 10, 2025, 11:51 PM EDT - 10 months ago

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Feb 26, 2025, 7:02 AM EST - 11 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 11 months ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Feb 11, 2025, 8:30 AM EST - 1 year ago

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Jan 7, 2025, 11:31 AM EST - 1 year ago

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Dec 25, 2024, 7:31 AM EST - 1 year ago

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Dec 17, 2024, 8:30 AM EST - 1 year ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Nov 18, 2024, 8:30 AM EST - 1 year ago

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Oct 30, 2024, 10:57 PM EDT - 1 year ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 1 year ago

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Day One Announces Oversubscribed $175.0 Million Private Placement

Jul 25, 2024, 12:58 AM EDT - 1 year ago

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Jun 18, 2024, 8:30 AM EDT - 1 year ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

May 30, 2024, 8:30 AM EDT - 1 year ago

Day One Announces Sale of Priority Review Voucher for $108 Million

May 6, 2024, 4:30 PM EDT - 1 year ago

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

$Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor$

Apr 23, 2024, 3:56 PM EDT - 1 year ago

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Feb 26, 2024, 4:30 PM EST - 2 years ago

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Feb 1, 2024, 10:07 AM EST - 2 years ago

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Dec 19, 2023, 8:00 AM EST - 2 years ago

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 17, 2023, 7:00 AM EST - 2 years ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Nov 6, 2023, 4:30 PM EST - 2 years ago

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Sep 15, 2023, 3:21 PM EDT - 2 years ago

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Sep 11, 2023, 9:02 PM EDT - 2 years ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

GriZlyBeAr Jan. 21 at 12:53 AM

$DAWN holy fook

1 · Reply

Buckeye80 Jan. 21 at 12:53 AM

$DAWN bid 13.20

0 · Reply

MeganF0x Jan. 21 at 12:04 AM

0 · Reply

Xanderzzzzzzz Jan. 20 at 11:24 PM

$DAWN

0 · Reply

Buckeye80 Jan. 20 at 11:18 PM

$DAWN bid 12.50

0 · Reply

GriZlyBeAr Jan. 20 at 10:11 PM

$DAWN zero sellers, you can sell if you want, looks like there is plenty on the bid

0 · Reply

GriZlyBeAr Jan. 20 at 9:54 PM

$DAWN love that this is under the radar with less than 2000 watchers

2 · Reply

GriZlyBeAr Jan. 20 at 9:44 PM

$DAWN all the shares are locked by insiders and institutions…when do the shorts cover…

0 · Reply

copywrites Jan. 20 at 9:36 PM

$DAWN still running AH

1 · Reply

GriZlyBeAr Jan. 20 at 9:32 PM

$DAWN 👀

0 · Reply

TrustButVerifi Jan. 20 at 9:32 PM

$DAWN they pre announced $220 - $250 million revenue for Ojemda (peak sales 600-800 million) MC 1.2 Billion 11 million Short 2-3 X BO coming imo!

0 · Reply

RunnerSignals Jan. 20 at 9:10 PM

Top Stock Market Warriors $SIDU $DAWN $LPTH $AMLX $APPS started the day in the red but fought back like true Market Warriors, ending up double-digit gains!

0 · Reply

TrustButVerifi Jan. 20 at 8:45 PM

$DAWN Novartis buying this?

3 · Reply

ngnol Jan. 20 at 8:29 PM

$DAWN come on give us the BO PR!

1 · Reply

Buckeye80 Jan. 20 at 8:23 PM

$DAWN something is cooking

0 · Reply

copywrites Jan. 20 at 8:12 PM

$DAWN break out... with volume News pending

1 · Reply

TheMach99 Jan. 20 at 7:06 PM

$DAWN Something big definitely going on here. Serious volume and price action.

1 · Reply

TheMach99 Jan. 20 at 4:44 PM

$DAWN $24-27/share fits Ipsen's financial bandwidth.

1 · Reply

Starlord10 Jan. 20 at 4:16 PM

$DAWN BO (buyout) would be ideal

0 · Reply

TheGunnerAB Jan. 20 at 3:19 PM

$DAWN 20,000 of April $11 calls were bought, average premium of $2.8 or $5.6M in premium. I'm praying it's not the same guy from the December and January calls.

1 · Reply

copywrites Jan. 20 at 3:08 PM

$DAWN 👀

0 · Reply

Alien1980 Jan. 20 at 2:57 PM

Add these to your watchlist, trust me 👽👽 $DPRO $USAR $DAWN $PDYN all relatively strong Chart your entries, but they all should go 🛸🛸

1 · Reply

Market Cap	1.04B
Revenue (ttm)	131.16M
Net Income (ttm)	-95.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-72.81%
Debt to Equity Ratio	0.00

Volume	6,972,100
Avg Vol	3,004,012
Day's Range	N/A - N/A
Shares Out	102.68M
Stochastic %K	54%
Beta	-1.27
Analysts	Strong Sell
Price Target	$22.25